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Background: Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD) may increase
the risks of arrhythmia and sudden death. We studied cardiac autonomic function in patients with acute
exacerbation of COPD (AECOPD).
Methods: Patients with AECOPD were classified into ventricular tachycardia (VT) and non-VT groups according to
the presence or absence of VT. The following parameters derived from 24-h Holter monitoring were compared
between groups: average heart rate, heart rate deceleration capacity (DC), heart rate acceleration capacity (AC),
standard deviation of normal RR intervals (SDNN), standard deviation of average RR interval in 5-min segments
(SDANN), root mean square of standard deviations of differences between adjacent normal RR intervals (rMSSD),
low-frequency power (LF), high-frequency power (HF) and LF/HF ratio.
Results: Seventy patients were included, 22 in the VT group and 48 in the non-VT group. The groups had similar
clinical characteristics (except for more common amiodarone use in the VT group, P < 0.05) and general ECG
characteristics. DC, SDNN, SDANN and rMSSD were lower and AC higher in the VT group (P < 0.05). In the VT group,
DC was correlated positively with SDNN (r = 0.716), SDANN (r = 0.595), rMSSD (r = 0.571) and HF (r = 0.486), and
negatively with LF (r = -0.518) and LF/HF (r = -0.458) (P < 0.05). AC was correlated negatively with SDNN (r = -0.682),
SDANN (r = -0.567) and rMSSD (r = -0.548) (P < 0.05).
Conclusions: DC decreased and AC increased in patients with AECOPD and VT, reflecting an imbalance in
autonomic regulation of the heart that might increase the risk of sudden death.
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Chronic obstructive pulmonary disease (COPD) is a com-
mon, serious lung disease that impacts severely on patient
quality of life. COPD inflicts a heavy financial burden on
patients, their families and society, and its incidence and
mortality rate have gradually increased in recent years [1].
In the USA, the mortality and incidence of COPD rank
third and second, respectively, of all diseases [2]. COPD
incidence in China is 8.2 % in those older than 40 years,
and the disease ranks fourth and third among causes of
death in urban and rural areas, respectively [3]. Cardiovas-
cular diseaseis the leading cause of death in mild to mod-
erate COPD, but those with severe disease more common
die of respiratory failure, and in some cases mortality is
associated with the occurrence of arrhythmia [4, 5]. About
31.9 % of patients with COPD suffer from ≥ 30 premature
ventricular beats per hour, and the incidences of non-
sustained and sustained ventricular tachycardia (VT) are
13.0 % and 1.6 %, respectively [6]. Furthermore, COPD
and its severity correlates independently with non-
sustained VT [6].
The pathogenesis of COPD is not fully understood. In-
halation of deleterious particles/gases tends to induce pul-
monary oxidative stress, an imbalance between protease
and antiprotease function, and the generation of inflam-
matory mediators that recruit neutrophils, damage pul-
monary structures and restrict airflow [7]. Autonomic
nervous system (ANS) dysfunction is now recognized as
playing an important role associated with COPD patho-
genesis [7]. Sympathetic autonomic nerves act to quicken
the heart and strengthen the heart rate acceleration cap-
acity (AC). In contrast, the vagal nerve slows the heart
rate and enhances the heart rate deceleration capacity
(DC). An imbalance between these two arms of the ANS
can promote the occurrence of lethal arrhythmia [8, 9].
An acute exacerbation of COPD (AECOPD) aggravates
the airflow obstruction and imbalance in autonomic func-
tion, potentially resulting in malignant arrhythmia and
sudden cardiac death [10–12].
Various non-invasive diagnostic techniques are com-
monly used to assess cardiac autonomic function in pa-
tients with COPD, including the Ewing test, heart rate
variability (HRV), baroreflex sensitivity (BRS), heart rate
turbulence (HRT), and cardiac chronotropic and QT
interval analysis. The Ewing test is a cardiovascular reflex
examination involving 5 items [13], but has certain limita-
tions, such as the necessity for active cooperation of the
patient and manual implementation, and a susceptibility
to subjective factors. The other commonly used tech-
niques for testing autonomic function also have limita-
tions, as most rely on indirect methods such as detection
of physiologic parameters regulated by autonomic nerves.
For example, the indirect reflex regulation of blood pres-
sure and heart rate by autonomic nerves is used as thebasis for HRV and HRT measurements. It is also difficult
to differentiate between the effects of sympathetic and
vagal nerves since a change in the parameter measured re-
flects the combination of their influences, leading to quali-
tative rather than quantitative assessments in most cases.
Moreover, it can be challenging to distinguish between the
effects of physiologic and pathologic factors. An additional
drawback of some techniques is that assessments can only
be made under certain conditions. For example, HRT
measurements can only be carried out after the appear-
ance of ventricular premature beats, and BRS can only be
determined by the injection of phenylephrine.
Measurements of DC and AC tend to avoid many of
the limitations described above. DC and AC can quanti-
tatively assess vagal and sympathetic nerve tone over a
24-h period, and screening of DC can provide an early
warning to patients at high risk of sudden death [14].
The phase rectified signal average (PRSA) technique can
extract periodic signals from a complicated time series
consisting of periodic cardiac electrical signals contami-
nated with variable signal noise and artifacts. An advan-
tage of this method is that no other treatments are
needed, minimizing the number of factors that might
affect the measurements, thereby improving specificity
and sensitivity. The PRSA techniqueis thought to be su-
perior to other traditional methods in the detection of
quasi-periodic signals in long-duration heart rate records
that represent the regulatory function of cardiac auto-
nomic nerves. Thus, the data provided by this approach
likely have high clinical relevance.
Several studies have reported that DC is significantly
decreased in patients with acute myocardial infarction,
diabetes mellitus and COPD, and can be used as an indi-
cator of autonomic function and an early warning of
sudden death [14–18]. Our previous study indicated
both DC and AC of heart rate decreased in patients with
hemispheric infarction,reflecting a decrease in both vagal
and sympathetic modulation [19]. However, there are
few data concerning the utility of DC as a gauge of car-
diac autonomic function in patients with AECOPD. The
aim of this study was to measure the changes in DC and
AC in patients with AECOPD accompanied with VT,
and investigate the role of these parameters in the evalu-
ation of cardiac autonomic function by determining their
correlations with other commonly used indicators.
Methods
Patients
This was a retrospective observational study of patients
with AECOPD and arrhythmia admitted to the Sixth Peo-
ple’s Hospital affiliated with Shanghai Jiao Tong University
(Shanghai, China) between March 2010 and March 2014.
Seventy patients were included, and AECOPD was diag-
nosed based on the 2013 criteria of the Global Initiative
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bations were defined as events of acute onset, character-
ized by a worsening of the patient’s respiratory symptoms
(baseline dyspnea, cough, and/or sputum production) that
is beyond normal day-to-day variations and leads to a
change in medication. Arrhythmias were defined as iso-
lated premature atrial beats, supraventricular tachycardias,
isolated and paired premature ventricular complexes, and
combined ventricular arrhythmias consisting in ventricu-
lar tachycardias. Details of the medical history, clinical
examination and supplementary investigations were
obstained from medical records, and patients were
excluded from the analysis if any of the following
exclusion criteria applied: hypertension; previous acute
myocardial infarction; diabetes mellitus; severe liver
or kidney dysfunction; tumors; anemia; drugs that
might affect HRV (e.g. β-adrenoceptor antagonists);
basal heart rate not in sinus rhythm (e.g., atrial fibril-
lation or flutter); and an implanted pacemaker. The
study was approved by the ethics committee of the
Sixth People’s Hospital affiliated with Shanghai Jiao
Tong University. All patients provided informed
written consent for their anonymized data, including
electrocardiogram (ECG), to be analyzed and included
in a subsequent research study.
Study design
Patients were allocated into two groups: a VT group (VT
present) or a non-VT group (VT absent). VT was de-
fined as at least three consecutive ventricle-originated
extrasystoles occurring at a frequency of > 100 beats/min
in the dynamic ECG.VT was classified as non-sustained
if it persisted for < 30 s, and sustained if it persisted for
30 s or more [21].
Collection of clinical data
The following data were obstained from the medical
records: patient gender; patient age; smoking expos-
ure, and concurrent medications, including β2-adreno-
ceptor agonists, anticholinergics, calcium channel
antagonists, amiodarone and hormone replacement
therapy. Biochemical analyses, including blood urea
nitrogen (BUN), serum creatinine (Cr), fasting blood
glucose (FBG) and serum total cholesterol (TC), arter-
ial blood gas analyses and electrolytes, were carried
out on the day following admission. The Modified
British Medical Research Council(mMRC) question-
naire on breathlessness was used to assess symptoms
[22]. Echocardiographic measurement of left ventricu-
lar ejection fraction (LVEF) was performed within
1 week of admission. Dynamic electrocardiography
was carried out within 1 week of admission to obtain
measurements of minimum, maximum and average
heart rates and assess the characteristics of prematureventricular beats (when present). Echocardiography
and ECG investigations were performed by experi-
enced physicians, and offline data analysis was per-
formed by experienced clinicians, who were blind to
the patient grouping. None of the enrolled patients
underwent pulmonary function testing as part of this
study.Measurement of DC and AC
All patients underwent 24-h Holter monitoring, and
the data were analyzed offline using a DMS dynamic
cardiograph analysis system (DM Software, NV, USA).
Interference and artifacts were removed through the
man-machine dialog, and DC and AC values were cal-
culated automatically by the analysis system. The ana-
lysis was performed by a certified ECG technician
supervised by a cardiovascular physician (both blind to
the study hypothesis).
DC was measured as follows [14]: the deceleration period
was screened from the 24-h dynamic ECG using a 4096 Hz
sampling frequency digital automatic processing system,
with the size of the heart rate segment was fixed at 20 cycles
(i.e., RR intervals). The deceleration point of a prolonged
cardiac cycle compared with the previous one was selected
as the ‘anchor point’ for ordered arrangement of different
heart rate segments, and mean values were calculated for
the following parameters: X0, the mean of the RR intervals
for all anchor points; X1, the mean of the RR intervals for
all the cardiac cycles immediately following the anchor
points; X-1, the mean of the RR intervals for all the cardiac
cycles immediately preceding the anchor points; and X-2,
the mean value of the RR intervals for all the cardiac cycles
immediately preceding the X-1 points. The mean values of
X0, X1, X-1 and X-2 were calculated separately, and the DC
value calculated as: DC (ms) = (X0 +X1 – X-1 – X-2)/4.
The acceleration period was screened using similar
methods, and the calculated parameters were substituted
into the above formula to obtain the AC value, which
was negative.Assessment of HRV
Each HRV index was calculated automatically using the
DMS analysis software. The time-domain indexes (units,
ms) included: SDNN (the standard deviation of all nor-
mal RR intervals), SDANN (the standard deviation of
the average normal RR intervals in all 5-min segments)
and rMSSD (the root mean square value of the standard
deviations of the successive differences between adjacent
normal RR intervals in the whole 24-h period). The
frequency-domain indexes (units, ms2) included: LF
(low-frequency power), HF (high-frequency power) and
the LF/HF ratio.







Gender (male) 31 (64.5 %) 15 (68.2 %) 0.77
Age (years) 61.2 ± 11.4 60.6 ± 11.8 0.86
BUN (mmol/L) 6.0 ± 1.5 6.1 ± 1.2 0.84
Cr (μmol/L) 76.3 ± 15.8 77.1 ± 15.2 0.82
FBG (mmol/L) 5.0 ± 0.9 5.1 ± 0.8 0.79
TC (mmol/L) 4.8 ± 0.6 4.7 ± 0.7 0.83
LVEF (%) 59.8 ± 6.4 58.7 ± 6.5 0.87
β2 agonist use 45 (93.8 %) 20 (90.9 %) 1.00
Anticholinergic use 40 (83.3 %) 19 (86.4 %) 1.00
Hormone replacement therapy 36 (75.0 %) 17 (77.3 %) 0.84
Calcium antagonist use 15 (31.2 %) 10 (45.5 %) 0.25
Amiodarone use 5 (10.4 %) 15 (68.2 %) <0.05
Smoker 10 (20.8 %) 6 (27.3 %) 0.64
PH 7.40 ± 0.05 7.41 ± 0.08 0.13
PaO2(mmHg) 60.5 ± 5.9 59.8 ± 5.3 0.73
PaCO2(mmHg) 49.4 ± 5.6 50.5 ± 5.9 0.43
Serum K+(mmol/L) 4.2 ± 0.4 4.1 ± 0.4 0.25
Serum Na + (mmol/L) 138.8 ± 3.3 139.7 ± 3.2 0.12
Serum Cl-(mmol/L) 99.8 ± 2.0 98.8 ± 2.2 0.06
mMRC Grade 0 10 (20.8 %) 5 (22.7 %) 0.88
mMRC Grade 1 15 (31.2 %) 6 (27.3 %) 0.80
mMRC Grade 2 12 (25 %) 5 (22.7 %) 0.87
mMRC Grade 3 8 (16.7 %) 4 (18.2 %) 0.89
mMRC Grade 4 3 (6.3 %) 2 (9.1 %) 0.69
Data presented as n (%) or mean ± standard deviation
BUN blood urea nitrogen, Cr serum creatinine, FBG fasting blood glucose, LVEF
left ventricular ejection fraction, TC serum total cholesterol, VT ventricular
tachycardia, mMRC modified British Medical Research Council questionnaire
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Statistical analyses were performed using SPSS16.0 software
(SPSS Inc., Chicago, IL, USA). All measurement data were
subjected to tests of normality. Normally distributed data
are reported as the mean ± standard deviation. For nor-
mally distributed data, comparisons between groups were
performed using Student’s t-test, and correlations between
variables analyzed using Pearson correlation analysis. Data
not normally distributed were analyzed with Spearman cor-
relation analysis. Count data are expressed as number of
cases and percentages, and comparisons between groups
were performed using the χ2 test. P < 0.05 was considered
statistically significant.
Results
Clinical characteristics of the patients
Seventy patients were included in the final analysis, 22
(aged 50–78 years) in the VT group and 48 (aged 51–
79 years) in the non-VT group. The clinical characteris-
tics of these patients are presented in Table 1. The pro-
portion of patients taking amiodarone was significantly
higher in the VT group than in the non-VT group
(68.2 % vs. 10.4 %, P < 0.05). There were no significant
differences between groups in the other clinical charac-
teristics (Table 1).
Comparison of general Holter recordings characteristics
between the VT and non-VT groups
Of 22 patients with VT, 20 (90.9 %) had non-sustained
VT and 2 (9.1 %) had sustained VT (Table 2). Therefore,
non-sustained VT and sustained VT occurred in 28.6 %
and 2.9 % of all patients with AECOPD in our study.
There were no significant differences between the non-
sustained VT and sustained VT groups in the general
Holter recordings parameters assessed (average, minimal
and maximal heart rate, mean ventricular premature
beats, and proportion of patients with ≥ 30 ventricular
premature complexes/hour; Table 2).
Comparison of DC, AC and HRV parameters between the
VT and non-VT groups
Patients in the VT group had a lower DC, SDNN, SDANN
and rMSSD, and a higher AC, than patients in the non-
VT group (all P < 0.05; Table 3). However, there were no
significant differences between the VT and non-VT groups
in LF, HF and LF/HF (Table 3).
Correlations of DC and AC with HRV parameters in the VT
group
In the VT group, DC was correlated positively with SDNN,
SDANN, rMSSD and HF, and negatively with LF and LF/
HF (P < 0.05; Table 4). AC was correlated negatively with
SDNN, SDANN and rMSSD (P < 0.05), but was not corre-
lated with LF, HF and LF/HF (Table 4).Discussion
The main findings of the present study were that, in
Chinese patients with AECOPD, those with VT had a
lower DC, SDNN, SDANN and rMSSD, and a higher
AC, than those without VT. Furthermore, DC was cor-
related positively with SDNN, SDANN, rMSSD and HF,
and negatively with LF and LF/HF, while AC was corre-
lated negatively with SDNN, SDANN and rMSSD. These
data indicate that patients with AECOPD and VT have
greater impairment of cardiac autonomic function than
patients without VT, suggesting that these patients may
also be at increased risk of sudden death.
In patients with COPD, the effects of chronic airflow ob-
struction on the cardiovascular system and cardiac auto-
nomic nerves manifest mainly as a limitation of mobility,
cardiac autonomic dysfunction, increased resting heart rate
and decreased BRS [7, 23]. Impaired autonomic function
Table 2 Comparison of the general Holter recordings






Average heart rate (beats/min) 79.5 ± 13.8 81.2 ± 15.8 0.83
Minimal heart rate (beats/min) 70.5 ± 13.6 73.8 ± 15.3 0.86
Maximal heart rate (beats/min) 90.1 ± 16.4 94.8 ± 17.2 0.86
Mean ventricular premature
beats
1257.3 ± 251.7 1326.2 ± 268.5 0.83
Ventricular premature
complexes≥ 30/h
19 (39.6 %) 9 (40.9 %) 0.92
Non-sustained VT 0 20
Sustained VT 0 2
Data presented as n (%) or mean ± standard deviation
VT ventricular tachycardia
Table 4 Correlations of DC and AC with HRV parameters in the
VT group
Variable DC AC
r P r P
SDNN (ms) 0.716 <0.001 -0.682 <0.001
SDANN (ms) 0.595 0.005 -0.567 0.006
rMSSD (ms) 0.571 0.007 -0.548 0.008
LF (ms2) -0.518 0.038 0.413 0.057
HF (ms2) 0.486 0.043 -0.398 0.062
LF/HF ratio -0.458 0.041 0.387 0.060
AC acceleration capacity of the heart rate, DC deceleration capacity of the
heart rate, HF high-frequency power, LF low-frequency power, rMSSD the root
mean square value of the standard deviations of the successive differences be-
tween adjacent normal RR intervals in the whole 24-h period, SDANN the
standard deviation of the average normal RR intervals in all 5-min segments,
SDNN the standard deviation of all normal RR intervals
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striction, aggravation of hypoxia, and progression of COPD
[24]. Patients with AECOPD and hypoxemia may experi-
ence long-term atrial and ventricular hypoxia, leading to in-
creased sympathetic nerve activity, decreased vagal nerve
activity, impaired sinus node function, an acceleration of
the heart rate, a shortening of the diastolic interval and
hence reduced myocardial perfusion, increased myocardial
oxygen consumption, increased levels of byproducts of
local ischemia, a declined ventricular fibrillation threshold,
increased occurrence of malignant arrhythmias and in-
creased risk of sudden cardiac death [10, 11].
The results of the present study show that the VT group
had a lower DC value and higher AC value than the non-
VT group, suggesting that patients with AECOPD and VT
suffer from enhanced sympathetic nerve activity, weakened
vagal nerve activity and impaired autonomic nervous func-
tion, as compared to patients with AECOPD in the absenceTable 3 Comparison of DC, AC and HRV parameters between
patients in the VT and non-VT groups
Variable Non-VT group (n = 48) VT group (n = 22) P
DC (ms) 5.62 ± 1.75 4.13 ± 1.72 0.036
AC (ms) -5.82 ± 1.84 -4.76 ± 1.69 0.040
SDNN (ms) 78.7 ± 22.1 68.2 ± 19.8 0.041
SDANN (ms) 68.7 ± 11.0 58.5 ± 10.5 0.043
rMSSD (ms) 21.3 ± 8.2 14.6 ± 6.2 0.045
LF (ms2) 1152.2 ± 440.5 1250.2 ± 408.6 0.068
HF (ms2) 221.5 ± 34.1 210.8 ± 27.6 0.071
LF/HF ratio 5.1 ± 2.0 5.9 ± 2.5 0.070
Data presented as the mean ± standard deviation
AC acceleration capacity of the heart rate, DC deceleration capacity of the
heart rate, HF high-frequency power, LF low-frequency power, rMSSD the root
mean square value of the standard deviations of the successive differences be-
tween adjacent normal RR intervals in the whole 24-h period, SDANN the
standard deviation of the average normal RR intervals in all 5-min segments,
SDNN the standard deviation of all normal RR intervals, VT
ventricular tachycardiaof VT. This would tend to induce electrophysiologic in-
stability in the heart, which can lead to aggravation of pre-
existing abnormal endocardial electric activity in patients
with non-sustained VT, increasing the risks of lethal reen-
trant VT and sudden cardiac death [10, 11, 25]. Notably,
28.6 % of patients in the present study had non-sustained
VT, higher than the value reported by Konecny et al. [6]. A
possible explanation is that the present study enrolled only
patients with AECOPD, in whom autonomic function im-
pairment was likely more severe than that in patients with-
out AECOPD.
Although AECOPD is thought to aggravate airflow
obstruction, worsen respiratory symptoms and exacerbate
ANS imbalance, the underlying mechanisms remain in-
completely understood. One possibility is that airway ob-
struction during AECOPD leads to carbon dioxide
retention and hypoxia, stimulating carotid sinus chemore-
ceptors and pulmonary stretch receptors to strengthen
sympathetic nerve activity and reduce vagal tone [26–28].
Another possibility is that patients with AECOPD may
have right atrial and ventricular enlargement, ventricular
wall hypertrophy and atrophy, and interstitial edema. Nec-
rotic lesions may have been replaced by fibrous tissue,
leading to a decrease in the number of vagal receptors,
and thus increased sympathetic nerve activity. A third po-
tential mechanism is that, normally, the right sympathetic
and vagal nerves dominate the sinus node, with sympa-
thetic nerves distributed along the epicardium, and vagal
nerves distributed along the endocardium. Long-term
hypoxia-ischemia in the right atrium and ventricle will
stimulate baroreceptors and chemoreceptors in the atrio-
ventricular wall, mainly damaging the vagal nerve fibers
and leading to a decreased DC.
HRV can be used to assess sympathetic and vagal tone
and balance, and their impact on cardiovascular activity.
A decreased HRV was suggestive of impaired cardiac
autonomic function, and was associated with increased
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that SDNN, SDANN, rMSSD and HF were lower in the
VT group than in the non-VT group, indicating significant
impairment of cardiac autonomic function; this is consist-
ent with previously published results [31, 32]. In the VT
group, DC correlated positively with SDNN, SDANN,
rMSSD and HF, and negatively with LF and LF/HF, while
AC correlated negatively with SDNN, SDANN and
rMSSD. This suggests that DC and AC correlate well with
more traditional indicators of autonomic function.
Under normal conditions, heart rate regulation by ANS
is subtle and rapid, such that changes can occur from one
cardiac cycle to the next. This is reflected in each cardiac
cycle, and these regulatory ‘signatures’ of the autonomic
nerves can be extracted as DC and AC using PRSA tech-
nology. DC and AC provide separate quantitative analyses
of the effects of vagal and sympathetic nerves system, with
pathologic changes in DC thought to be of greater clinical
significance than changes in AC [14]. In the 24-h ECG, a
prolonged cardiac cycle compared with the preceding one
is indicative of heart rate deceleration brought about by
the vagal nerve. Therefore, DC can be used to assess vagal
activity, and could potentially be used in screening to
identify patients at high risk of sudden death. Further-
more, the techniques required for determination of DC
and AC are straightforward to use and do not require im-
position of specific conditions or additional interventions
such as administration of drugs. Thus, PRSA technology
is capable of quantitatively assessing the effects of vagal
and sympathetic nerves with high reliability, sensitivity
and specificity, and has advantages over alternative com-
monly used approaches [13].
We studied cardiac autonomic function in patients with
AECOPD, and found that DC is decreased and AC in-
creased in patients with AECOPD and VT. However, there
are several limitations to our study. First, this was a retro-
spective study, hence selection and reporting bias cannot
be excluded. Second, the sample size was small, so the
study may have been underpowered to detect real differ-
ences for some comparisons. Third, this was a single-center
study, and the cohort may not be representative of the gen-
eral patient population in China or elsewhere. Fourth, com-
parator groups (e.g. age-matched patients with COPD but
without an acute exacerbation, and age-matched healthy
controls) were not included, precluding the determination
of whether autonomic dysfunction in patients with
AECOPD is greater than that in patients with COPD not
experiencing acute exacerbation or healthy individuals.
Fifth, patients taking drugs that might affect ANS function
and atrial fibrillation/flutter were excluded from the study,
which would have resulted in a degree of bias in patient se-
lection. Sixth, some patients in the VT group were receiving
β2-agonists, anticholinergics, hormones; these drugs may
have influenced the parameters measured using PRSA.Seventh, It was reported that amiodarone did not decrease
time domain measures of HRV in patients with chronic
ventricular arrhythmia [33]. There are no data available re-
garding the influence of amiodarone on the PRSA-derived
cardiac indices, but it is possible that it would be a potential
confounder on the autonomic nervous system and thus on
the measured parameters. Therefore, multi-center, pro-
spective studies with a larger sample size are merited to
confirm and extend our findings.
Conclusions
The present study determined that DC is reduced in pa-
tients with AECOPD accompanied by VT, reflecting an im-
balance in cardiac autonomic regulation that, potentially,
could increase the risk of sudden death. This suggests that
clinical intervention in patients with AECOPD and VT
should not only focus on actively improving ventilation, re-
ducing inflammation and suppressing arrhythmia, but also
target ANS dysfunction to maintain myocardial electrical
stability, elevate the ventricular fibrillation threshold, and
reduce the risk of sudden death.
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